- Trial phase
- Phase 2 (pivotal)
- Time to market
- NDA submission planned for Q1 2027 under accelerated approval pathway. If accepted and approved under standard review timelines, potential FDA decision could come in late 2027 or early 2028.
- Why 8/10
- The next hard, dated catalyst is the late-breaking oral presentation of updated pivotal Phase 2 PYNNACLE data at the ENA 2026 symposium on November 20, 2026 (roughly 9 days from today). Rezatapopt is PMVP's only clinical-stage asset and drives essentially the entire company valuation, making this a high-impact event. The NDA submission planned for Q1 2027 is the subsequent major binary.
The next catalyst is the late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 on November 20, 2026, roughly 9 days away. Positive data could reinforce the NDA submission narrative and support the stock, while disappointing results (weaker efficacy or safety signals) could undermine the accelerated approval path. The NDA submission itself, planned for Q1 2027, is the next major binary event after ENA.
Price Chart
Executive Summary
Rezatapopt (PC14586) is PMV Pharmaceuticals' lead and only clinical-stage asset, a first-in-class oral small molecule that reactivates the mutant p53 Y220C tumor suppressor protein found in about 1% of solid tumors. In August 2026, the company reported a 46% overall response rate with a 10-month median duration of response in 76 evaluable platinum-resistant/refractory ovarian cancer patients from the pivotal Phase 2 PYNNACLE trial. The FDA granted Fast Track and Orphan Drug designations in October 2026. The company plans to submit an NDA for accelerated approval in Q1 2027. The next catalyst is a late-breaking oral presentation of updated PYNNACLE data at the ENA 2026 symposium on November 20, 2026. PMVP trades at $1.26 with a strong buy analyst consensus and a mean price target of $4, implying roughly 228% upside.
How It Works
Rezatapopt is an oral small molecule designed to fix a broken tumor-suppressor protein called p53. In about 1% of solid tumors, a specific mutation (Y220C) creates a small pocket in the p53 protein that causes it to misfold and stop working. Rezatapopt fits into that pocket like a key, stabilizing the protein and restoring its ability to suppress tumor growth. It is taken as a pill and targets only cancer cells carrying this specific mutation.
Trial Status
The pivotal Phase 2 PYNNACLE trial (NCT04585750) is evaluating rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors. The ovarian cancer cohort has reported a 46% ORR among 76 evaluable patients with a median duration of response of 10.0 months. Updated data across tumor types will be presented as a late-breaking oral presentation at ENA 2026 on November 20, 2026.
The Two-Sided Case
Upcoming Catalysts
- Late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 (38th EORTC-NCI-AACR Symposium) on November 20, 2026
- NDA submission for accelerated approval in platinum-resistant/refractory ovarian cancer planned for Q1 2027
- Potential FDA acceptance of NDA and priority review designation in 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PMV Pharmaceuticals, Inc. 8-K PMVP ·Originating report